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Abstract: Poor sleep quality is a prevalent health problem among patients with 
diabetes. Metabolic syndrome (MetS) is common in type 2 diabetic patients and 
associated with morbidity and mortality. We aimed to investigate sleep quality among 
type 2 diabetes patients according to their metabolic syndrome status. This was an 
analysis of data collected from 189 adult type 2 diabetic patients. The patients divided 
into two groups (metabolic and non-metabolic) based on the presence of MetS. 
Anthropometric measurements, blood pressure, and serum glucose, lipid levels were 
collected. The Pittsburgh Sleep Quality Index (PSQI) calculated for all patients. There 
was no significant difference in subjective sleep quality scores between the two groups 
(p > 0.05). However, there was a significant difference in sleep latency scores between 
the two groups; the scores of patients with MetS were lower than those of patients 
without MetS (p = 0.010, p < 0.05).Sleep quality was low in 57.1% (n = 108) of patients 
with diabetes. Poor sleep is common among diabetic patients, but in this study, 
metabolic syndrome existence not associated with sleep quality in type 2 diabetic 
patients. 
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INTRODUCTION  
 Metabolic Syndrome (MetS) refers to a constellation of three or more of the 
following concomitant conditions that confer increased cardiovascular risk: abdominal 
obesity, hyperglycemia or insulin resistance, hypertriglyceridemia, reduced high-density 
lipoprotein levels, and hypertension. Patients fulfilling these criteria show an increased 
incidence of multiple health conditions1. An important application of this definition of 
MetS is in the daily clinical assessment of patients to identify those at with a higher risk 
of type 2 diabetes or cardiovascular disease. For patients with diabetes, MetS criteria 
can be useful to assess the risk of progression and cardiovascular disease risk. 
 Sleep deprivation reportedly reduces insulin sensitivity2, and poor sleep quality is 
a prevalent problem among patients with diabetes, and approximately 53.4% of the 
patients with diabetes experiencing poor quality of sleep compared to the 29% of the 
general population3.  
 In this study, we aimed to investigate the effect of MetS on sleep quality in 
diabetic patients.  Also, we investigated whether there is a relationship between sleep 
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quality and MetS components, such as blood triglyceride levels, fasting blood glucose, 
and waist circumference in patients with diabetes. Finally, we determined whether sleep 
problems are associated with MetS development. There is no study previously that 
compares sleep quality between two groups: Type 2 Diabetes patients with  Metabolic 
Syndrome and without Metabolic Syndrome. 
 
MATERIALS AND METHODS 
 Between 06.October.2017, and 02.October.2018, 189 randomly patients with 
type 2 diabetes who referred to the Endocrinology or Internal Medicine clinic who met 
the inclusion criteria were enrolled. The patients divided into two groups (metabolic and 
non-metabolic) based on the presence of MetS and written informed consent obtained 
before the data collection and analysis. The ethics committee approved the study of the 
Fatih Sultan Mehmet Hospital Clinical Research Ethics Committee (Istanbul, Turkey). 
 Exclusion Criteria: Exclusion criteria were the presence of known CVD, recent 
hospitalization for mental illness, neurologic disease, medication, or other health 
conditions that would affect the sleep cycle.  
 Anthropometric Measurements: Standard methods measured height and weight, 
and body mass index (BMI) calculated. Using a height measurement scale with an 
accuracy of 0.1 cm, heights of the patients were measured while they had no shoes on, 
we are in a standing position, looked straight ahead and put the shoulders and back of 
the feet in one direction. Using a weighing scale with an accuracy of 0.1 kg, weights of 
the patients were measured twice while they had no shoes on and wore minimum 
clothing and also after excretion. In the case of a difference of >0.1 kg between two 
measurements, the mean calculated after a third measurement. 
 BMI was calculated by dividing weight (in kg) by the square of height (in m). 
Patients with BMIs of <24.9, 25.0–29.9, and≥30.0 kg/ m2 classified as normal, 
overweight, and obese, respectively. Waist circumference measured using a steel 
measuring tape, with measurements made halfway between the lower border of the ribs 
and the iliac crest on a horizontal plane. Females with waist circumferences of 80–87.9 
cm and ≥88.0 cm were classified as overweight and obese, respectively.  
 The Pittsburgh Sleep Quality Index (PSQI) is a validated self-rated questionnaire 
that assesses sleep quality and disturbance over a 1-month time interval. In all, 19 
items generate seven component scores reflecting sleep problems in the areas of 
subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep 
disturbances, use of sleep medications, and daytime dysfunction. Each component is 
given a score between zero and three points. These scores are then combined to 
generate an overall PSQI score. The maximum PSQI score is 21 points, determined by 
the sum of the scores of all the seven components. Higher scores indicate the more 
reduced quality of sleep. It is common to classify subjects into two groups: good (PSQI 
≤ 5) and poor sleepers (PSQI > 5).  PSQI is an instrument that assesses subjective 
sleep quality and related disorders. The original validated instrument has 89.6% 
sensitivity and 86.5% specificity4. 
 Data collected from the face- to- face interviews conducted in a previously 
prepared, peaceful, and comfortable room. Subjects asked to sign a voluntary informed 
consent form before the interview.  
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 Statistical Analysis: Student's t-test used for two-group comparisons of the 
variables with normal distribution and the comparison of descriptive statistical methods 
(mean, standard deviation, median, frequency, ratio, minimum and maximum) as well 
as quantitative data. Mann–Whitney U test used for two-group comparisons. One-way 
ANOVA used for three-group comparisons of variables with a normal distribution. 
Pearson's chi-square test used for the comparison of qualitative data. Significance was 
evaluated at p < 0.05. NCSS (Number Cruncher Statistical System) 2007 (Kaysville, 
Utah, USA) used for statistical analysis. 
 
RESULT AND DISCUSSION 
 Of the 180 patients included in the study, 60.3% (n = 114) were females and 
39.7% (n= 75) were males. The average patient age was 55.10 ± 10.42 (range, 24–80 
years).  There was no significant difference in subjective sleep quality scores between 
the two groups (p > 0.05). However, there was a significant difference in sleep latency 
scores between the two groups; the scores of patients with MetS were lower than those 
of patients without MetS (p = 0.010, p < 0.05). However, sleep duration, usual sleep 
activity, sleep disturbance, sleep medication use, and daytime sleep dysfunction scores 
did not significantly differ between the two groups (p > 0.05).  
 The mean total PSQI scores of patients with and without MetS were 6.48 ± 4.05 
and 6.21 ± 3.56, respectively. However, there was no significant difference in total PSQI 
scores between the two groups (p > 0.05). There was no significant relationship found 
between triglyceride and PSQI total scores (p> 0.05). Finally, there was no significant 
relationship between BMI and PSQI total scores (p> 0.05), as evidenced by no 
statistically significant difference in total PSQI scores according to BMI. 
 
Table 1: Demographics Distribution 
 
Demographic features Category n (%) 
Age (n=180) 
years 
Min-Max (Median) 24-80 (56) 
Mean 55,10±10,42 
Gender 
Female 114 (60,3) 
Male 75 (39,7) 
Body weight (kg) (n=185) 
Min-Max (Median) 48-149 (88) 
Mean 88,59±15,69He 
Height (cm) (n=185) 
Min-Max (Median) 130-186 (161) 
Mean 161,99±8,86 
BMI (kg/m2) (n=185) 
Min-Max (Median) 21,2-50 (33) 
Mean 33,75±6,05 
Normal 8 (4,3) 
Overweight 40 (21,6) 
Obese 111 (60,0) 
Extreme Obese 26 (14 
Waist Circumference 
(cm) (n=177) 
Min-Max (Median) 61-148 (110) 
Mean 109,46±14,00 
Duration of Diabetes 
(year) (n=179) 
Min-Max (Meidan) 0,00-30 (10) 
Mean 9,15±6,65 
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Table 2: Metabolic Syndrome and Sleep Score 
 
Category  n (%) 
Metabolic syndrome 
- 51 (27,0) 
+ 138 (73,0) 
Metabolic Syndrome 
Criteria (+) 
Min-Max (Median) 1-5 (3) 
Mean ± Ss 3,20 ± 1,18 
Score 1 20 (10,6) 
Score 2 31 (16,4) 
Score 3 54 (28,6) 
Score 4 59 (31,2) 
Score 5 25 (13,2) 
Sleep Score 
Min-Max (Median) 0-44 (14) 
Mean ± Sd 14,66 ± 9,14 
 
 
 
Table 3: Distribution of Laboratory Results 
 
Laboratory Results 
HbA1c 
(n=167) 
Min-Max (Median) 5,2-15 (8,7) 
Mean ± sd 8,99±2,08 
Triglyceride 
(n=169) 
Min-Max (Median) 34-694 (162) 
Mean ± sd 194,95±112,51 
HDL 
(n=161) 
Min-Max (Median) 23-201 (42) 
Mean ± sd 45,13±20,63 
LDL 
(n=158) 
Min-Max (Median) 36-400 (124) 
Mean ± sd 127,72±46,87 
Blood Glucose 
(n=142) 
Min-Max (Median) 46-403 (180,5) 
Mean ± sd 194,49±79,46 
Systolic Blood 
Pressure 
(n=171) 
Min-Max (Median) 90-210 (140) 
Mean ± sd 142,90±23,11 
Diastolic Blood 
Pressure 
(n=170) 
Min-Max (Median) 50-180 (85) 
Mean ± sd 85,36±15,90 
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Table 4: Pittsburg Sleep Quality Components Mean In All Study Population 
 
Subjective Sleep Quality 
(n=183) 
Min-Max (Median) 0-3 (1) 
Mean ± Ss 1,20±0,94 
Sleep Latancy 
(n=187) 
Min-Max (Median) 0-3 (1) 
Mean ± Ss 1,22±0,98 
Sleep Duration 
(n=187) 
Min-Max (Median) 0-3 (0) 
Mean ± Ss 0,88±1,10 
Conventional sleeping 
activity (n=185) 
Min-Max (Median) 0-3 (1) 
Mean ± Ss 0,85±1,02 
Sleep Disorder 
(n=185) 
Min-Max (Median) 0-3 (1) 
Mean ± Ss 1,38±0,76 
Use of Sleep Medication 
(n=172) 
Min-Max (Median) 0-3 (0) 
Mean ± Ss 0,20±0,71 
Daytime Sleep Disorder 
(n=176) 
Min-Max (Median) 0-3 (0) 
Mean ± Ss 0,86±1,02 
PSQI Total Points 
(n=169) 
Min-Max (Median) 0-20 (6) 
Mean ± Ss 6,41±3,93 
<5 points 61 (36,1) 
≥5 points 108 (63,9) 
 
 
Table 5: Pittsburg Sleep Quality Index Components Between Groups 
 
Pittsburg Sleep Quality Index 
Metabolic 
syndrome (+) 
Metabolic 
syndrome (-) 
Subjective Sleep Quality 
(n=183) 
Min-Max (Median) 0-3 (1) 0-3 (1) 
Mean ± Ss 1,26±0,95 1,02±0,90 
Sleep Latancy  
(n=187) 
Min-Max (Median) 0-3 (1) 0-3 (1) 
Mean ± Ss 1,10±0,94 1,54±1,03 
Sleep Duration  
(n=187) 
Min-Max (Median) 0-3 (0) 0-3 (1) 
Mean ± Ss 0,80±1,08 1,08±1,16 
Conventional sleeping 
activity (n=185) 
Min-Max (Median) 0-3 (1) 0-3 (1) 
Mean ± Ss 0,84±1,00 0,90±1,07 
Sleep Disorder 
(n=185) 
Min-Max (Median) 0-3 (1) 0-3 (1) 
Mean ± Ss 1,41±0,75 1,30±0,79 
Use of Sleep Medication 
(n=172) 
Min-Max (Median) 0-3 (0) 0-3 (0) 
Mean ± Ss 0,24±0,77 0,07±0,46 
Daytime Sleep 
Disorder (n=176) 
Min-Max (Median) 0-3 (1) 0-3 (0) 
Mean ± Ss 0,92±1,05 0,72±0,91 
PSQI Total Points  
(n=169) 
Min-Max (Median) 0-20 (6) 0-16 (6) 
Mean ± Ss 6,48±4,05 6,21±3,56 
<5 points 48 (37,8) 13 (31,0) 
≥5 points 79 (62,2) 29 (69,0)  
aStudent t-Test cMann Whitney U Test *p<0,05 
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Table 6: Associations With PSQI 
 
 
PSQI total points p 
  
Min-Max 
(Median) 
Ave ± Ss  
Age (years) 
(n=180) 
r 0,082  
 p 0,302  
Sex Female 0-20 (6) 6,70±3,86 a0,251 
 Male 0-16 (5) 5,99±4,02  
 BMI (kg/m2) (n=185) r -0,040   
 p 0,611   
 Normal 1-12 (4) 5,43±4,50 d0,865 
 Light-Weighted 0-14 (6,5)    6,72±3,94  
 Obese 1-20 (6) 6,43±3,89  
 Extreme obese 0-16 (6)    6,15±4,34  
Diabetes duration 
(years)(n=179) 
r 0,073  
p 0,378  
 HbA1c (n=167) r 0,141  
 p 0,083  
 
 MetS ratio, determined according to the National Cholesterol Education Program 
Adult Treatment Panel III was 73% in patients with diabetes included in our study. This 
ratio has reported being 33.9% in the normal Turkish population5. In another study, this 
ratio was as high as 87.2 % in patients with diabetes6. MetS is associated with low 
sleep quality. A cross-sectional study has reported that night-shift work was 
independently associated with a two-fold increase in the risk of MetS. Moreover, night 
shift workers showed significantly poorer sleep quality, increased sleep latency, 
decreased sleep duration, sleep disturbances, and daytime dysfunction7. In another 
study, poor sleep quality was associated with insulin resistance in postmenopausal 
females with or without MetS. Females with the worst sleep quality showed significantly 
higher HOMA2-IR values than women in all other quartiles8.  
 In this study, the PSQI mean was 6,41±3,93.  Sleep quality was low in 57.1% (n 
= 108) of patients with diabetes. Reportedly, sleep disturbances and diabetes mellitus 
linked to impaired glucose tolerance9. In a study, 796 people, who slept for <5 hours per 
day, had more waist circumference and frequent MetS10. In the Sleep Heart Health 
Study, an increased risk of hypertension found in patients who slept for <6 hours or >8–
9 hours per day11.  According to a survey conducted at the University of Pittsburgh, 
patients with type 2 diabetes showed low PSQI scores. Sleep disorders were more 
frequent in diabetic patients than in healthy individuals (33.7% ([n = 184)] and 8.2% ([n 
= 99),], respectively; p <0.01)12. In a study conducted in Brazil, 48% of the patients 
showed poor sleep quality indicated by PSQI scores13. Another study in the United 
States, this rate was 55% of 300 patients, which is similar to the rate in our study14. 
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 The mechanism can be defined as sleep restriction that alters the ability of leptin 
to accurately signal energy balance or decreased leptin levels that may represent a 
normal adaptation in response to the increased calorie need of long-term alertness15. 
Sleep onset stops recovery after a meal and reduces ghrelin levels to morning fasting 
values. In a randomized crossover study by Spiegel in 2004, ghrelin levels increased by 
28% despite 2 hours of sleep16. This increase in ghrelin level following sleep loss has 
confirmed in subsequent studies17. After 4 hours of sleep for four days, glucagon-like 
peptide 1 (GLP-1) levels in the afternoon were lower in women but not in men. GLP-1 is 
a gut-derived peptide that delays gastric emptying and promotes saturation18. 
 The present study did not find any association between BMI and PSQI scores. 
Likewise, according to a study conducted in Turkey, there was no relationship between 
BMI and PSQI scores, and the females with poor sleep quality consumed significantly 
more bread, but no other foods, than the females with good sleep quality19. In a large-
scale study across six middles/low-income countries, no significant association of poor 
sleep quality with BMI and waist circumference found; however, high sleep quality found 
to be associated with high BMI and waist circumference in males in China and India. 
Different. These differences in patterns may be attributed to the socioeconomic 
differences between the two countries. Individuals with higher BMI in China and India 
have a higher socioeconomic status and may have been less exposed to adverse social 
stressors, subsequently reporting higher sleep quality scores20. Also, this study did not 
find any association between blood triglyceride and PSQI. This result was similar in 
other studies. It was similar to some studies in the literature21.  
 Therefore, our study proves that sleep disorders are common in patients with 
diabetes (57.1%); however, when classified based on the  MetS status, there was no 
significant difference in terms of sleep quality. This may be due to the socioeconomic 
structure of Turkey (BMI may be higher in patients with higher socioeconomic status 
and low-stress factors that can disrupt the sleep quality). and the advanced diabetes 
stage of our patients (mean HbA1c: 9.01% MetS diabetes with MetS and 8.7% diabetes 
without Mets. Another cognitive variant may be determined to assess the perception of 
sleep quality. 
 Limitations of this study include its single-center design and subjective 
assessment of sleep quality, Because of the high frequency of metabolic syndrome in 
diabetic patients, the group with MetS had more patients. Further data on sleep quality 
and MetS components may be obtained in large-scale studies, including more objective 
sleep assessments. 
 
CONCLUSION 
 Sleep quality is a prevalent problem in diabetic patients. It can be more beneficial 
to reveal the association between diabetes and sleep deeply, sleep quality. This may 
extend in future diabetes evaluation or treatment in a different place. It will be beneficial 
to make to reveal the association between diabetes and sleep quality in future large-
scale, multi-center studies in other regions.  
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